The Non-glycemic Effects of SGLT2 Inhibitor.

Lee,  Dae Ho

doi:2014.15.3.151

J Korean Diabetes > Volume 15(3); 2014 > Article

Focused Issue

The Journal of Korean Diabetes 2014;15(3):151-157.
DOI: https://doi.org/10.4093/jkd.2014.15.3.151 Published online September 30, 2014.

SGLT2 억제제의 혈당조절과 무관한 작용

이대호

The Non-glycemic Effects of SGLT2 Inhibitor.

Dae Ho Lee

Department of Internal Medicine, Wonkwang University School of Medicine & Hospital, Iksan, Korea. drhormone@naver.com

Abstract

Sodium glucose cotransporter 2 (SGLT2) inhibitors have recently been introduced as a new class of anti-diabetic agents. In addition to their glycemic action, SGLT2 inhibitors also have a number of non-glycemic effects that may contribute to renal and/or cardiovascular benefits. These include effects on tubuloglomerular feedback in the kidney, body weight, blood pressure, and serum uric acid. Other non-glycemic effects of SGLT2 inhibitors that need to be further studied include the effects on lipid profiles, food intake, and secretion of hormones such as leptin, incretins, and aldosterone. Also, the exact mechanisms of various non-glycemic actions should be further studied. Additionally, SGLT2 inhibitor therapy in combination with other drugs may have beneficial glycemic and non-glycemic effects.

Key Words: Diabetes mellitus, Sodium glucose cotransporter 2, Antidiabetic agent